Literature DB >> 27424978

NKD2 a novel marker to study the progression of osteosarcoma development.

X-Z Sun1, Y Liao, C-M Zhou.   

Abstract

OBJECTIVE: Osteosarcoma is the most frequent metastatic bone tumor in the current era. An effective novel marker is essential at the current scenario for the identification of the tumor and to treat them in the early stage of osteosarcoma. PATIENTS AND METHODS: In the present study, patients having metastatic and non-metastatic osteosarcoma samples were collected from the 23 patients along with the control. Microarray analysis was performed on both samples. The results were validated using Western blot analysis.
RESULTS: Microarray analysis confirms the up-regulation of NKD2 gene in the progression of osteosarcoma development. The results were validated using western blot analysis. Microarray in accordance with Western blot analysis helps to validate the expression of NKD2 in the progression of osteosarcoma development.
CONCLUSIONS: In short, NKD2 is the key molecular marker to study the progression of osteosarcoma development, and it may be used for better prognosis of the disease in early stage.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27424978

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  3 in total

1.  Logistic regression analysis for the identification of the metastasis-associated signaling pathways of osteosarcoma.

Authors:  Yang Liu; Wei Sun; Xiaojun Ma; Yuedong Hao; Gang Liu; Xiaohui Hu; Houlai Shang; Pengfei Wu; Zexue Zhao; Weidong Liu
Journal:  Int J Mol Med       Date:  2018-01-02       Impact factor: 4.101

2.  Expression of NF-κB and PTEN in osteosarcoma and its clinical significance.

Authors:  Teng Gong; Xuetao Su; Qun Xia; Jinggui Wang; Shilian Kan
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

3.  Identification of Kinesin Family Member 2A (KIF2A) as a Promising Therapeutic Target for Osteosarcoma.

Authors:  Zhe-Xiang Wang; Shao-Chun Ren; Zi-Song Chang; Jing Ren
Journal:  Biomed Res Int       Date:  2020-10-29       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.